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and Marius M Hoeper1,2Abstract
Objective: To determine the levels of circulating copeptin in patients with pulmonary arterial hypertension (PAH),
and to evaluate its relation with disease severity, outcome and response to treatment.
Background: Vasopressin is a key regulator of body fluid homeostasis. The co-secreted protein copeptin serves as
surrogate for plasma vasopressin levels and increases in acute and chronic left ventricular dysfunction. Copeptin has
not been studied in PAH.
Methods: Serum copeptin levels were evaluated in a retrospective cohort of 92 treatment-naïve patients with PAH,
39 patients with normal right ventricular hemodynamics (diseased controls) and 14 apparently healthy individuals
(healthy controls). In a second prospective cohort of 15 patients with PAH, serial changes of copeptin levels after
initiation of PAH treatment were measured. Copeptin levels were compared with clinical, biochemical and
hemodynamic parameters as well as response to treatment and clinical outcome.
Results: Circulating copeptin levels were elevated in PAH patients compared to diseased controls (20.1 pmol/l vs.
5.1 pmol/l; p = 0.001). Baseline levels of copeptin correlated with NYHA functional class (r = 0.46; p = 0.01), 6 minute
walking distance (r = −0.26; p = 0.04), NT-proBNP (r = 0.49, p = 0.01), creatinine (r = 0.39, p = 0.01) and estimated
glomerular filtration rate (r = −0.32, p = 0.01). Copeptin levels did not correlate with hemodynamics but decreased
after initiation of PAH therapy (p = 0.001). Elevated copeptin levels were associated with shorter survival (p < 0.001)
and independent predictors of mortality in a multiple Cox regression analysis (HR1.4; 95% confidence interval
1.1-2.0; p = 0.02).
Conclusions: Patients with PAH had elevated copeptin levels. High circulating levels of copeptin were independent
predictors of poor outcome, which makes copeptin a potentially useful biomarker in PAH.Introduction
Pulmonary arterial hypertension (PAH) is a disease char-
acterized by progressive remodeling of the pulmonary
vasculature, leading to right ventricular strain and subse-
quent right heart failure [1]. Several clinical, biochemical
and hemodynamic parameters are associated with out-
come [2] but survival in patients with PAH is mainly
dependent on preserved right ventricular function [3].
Common clinical symptoms of advanced right heart
failure are lower extremity edema resulting from volume
overload and disturbed body fluid homeostasis [3]. The* Correspondence: nickel.nils@mh-hannover.de
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reproduction in any medium, provided the orregulation of body fluid homeostasis in chronic heart
failure is complex and related to cardiac output and per-
ipheral arterial resistance [4].
To compensate for a decrease in effective circulatory
volume, the activation of neurohumoral reflexes medi-
ated by the sympathetic nervous system leads to activa-
tion of the renin-angiotensin-aldosterone system, and
the nonosmotic release of arginine vasopressin (AVP),
all of which result in sodium or water retention [5].
The levels of circulating AVP underlie a complex feed
forward and feedback regulation. Among the stimuli that
lead to AVP release are increased plasma osmolality, de-
creased arterial pressure, reduced cardiac filling and
neurohumoral peptides such as angiotensin [6].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ipheral effects by binding to tissue specific receptors.
The two predominant receptors for AVP are the vaso-
pressin 1(V1) and the vasopressin 2(V2) receptor. The V1
receptor mediates arteriolar vasoconstriction and the V2
receptor mediates water reabsorption via induction of
aquaporins in the collecting ducts of the kidney [7].
AVP has a short plasma half-life and is unstable in
isolated plasma [8]. In addition to that, 90% of the circu-
lating AVP protein is bound to platelets, resulting in vary-
ing AVP levels, depending on sampling handling and
storage.9,10 The small molecular size of the AVP protein
makes it not suitable for conventional sandwich immuno-
assays [9]. For all of these reasons, AVP measurements
have never become clinical routine.
AVP derives from a precursor protein, pre-pro-
vasopressin, which consists of a signal peptide, AVP,
neurophysin II, and copeptin [10]. These three peptides
are stochiometrically secreted from the posterior pituit-
ary [11]. Thus, copeptin levels can be used as a surrogate
of AVP release [9,12]. Copeptin is a well-established sur-
rogate marker for AVP-release that is stable ex vivo in
serum and plasma and therefore suitable for retrospect-
ive analyses [9].
Copeptin has been shown to be of prognostic import-
ance in a variety of cardiovascular pathologies [13-15].
In chronic left heart failure, increased levels of copeptin
were correlated with hyponatremia and independently
linked to excess mortality [14].
Compared to left heart disease the neurohumoral axis
is less extensively studied in patients with pulmonary
hypertension and right-sided cardiac dysfunction. Pa-
tients with PAH show increased sympathetic nervous
system activity, elevated levels of endothelin, norepin-
ephrine [16] renin and aldosterone [17,18] and it is
likely that the AVP system is also activated. Of note,
elevated plasma volume and low serum sodium con-
centrations are associated with excess mortality in
PAH patients [19,20].
In the present study we studied copeptin levels in pa-
tients with PAH and the potential role of copeptin as
biomarker in this disease.
Patients and controls
We included 107 patients with PAH (Group 1 Dana Point
classification) in this study. The first cohort was studied
retrospectively and consisted of 92, treatment-naïve pa-
tients with NYHA functional class II to IV referred to
Hannover Medical School between 2002 and 2010.
The second patient cohort was independent from the
first cohort and consisted of 15 consecutive patients
who were prospectively studied after they had been diag-
nosed with PAH. The PAH targeted therapy for the sec-
ond cohort is shown in Additional file 1: Table S2.In all patients, the diagnosis of PAH was based on
standard criteria with confirmation by right heart
catheterization and exclusion of other forms of pulmon-
ary hypertension by echocardiography, pulmonary func-
tion testing, chest X-ray, ventilation–perfusion scanning,
chest computed tomography angiography and laboratory
studies [3].
The first control group (healthy controls) consisted of
14 apparently healthy individuals with no medical his-
tory and who were on no medication. The second con-
trol group consisted of 39 age- and gender-matched
patients who were referred to our clinic for assessment of
pulmonary hypertension by right heart catheterization,
based on the suspicion of PAH by previous functional
heart evaluation. In all patients the diagnosis of PH/PAH
(defined by mPAP > 25 mmHg, PCWP < 15 mmHg) was
ruled out.
Baseline blood samples for the PAH cohorts and the
diseased controls cohort were collected at the time of
the initial right heart catheterization before the initiation
of any PAH-targeted therapy. In the second PAH cohort,
an additional blood sample was obtained during follow
up right heart catheterization after 3 to 6 months. All
blood samples were immediately cooled on ice and cen-
trifuged at 4°C. Serum samples were divided into ali-
quots and stored frozen at −80°C.
All patients and control individuals gave written, in-
formed consent for storage of serum samples and future
biomarker analyses at the time when the samples were
obtained, an approach that was approved by the insti-
tutional review boards of Medical School Hannover
(Nr. 3558).
Biochemical measurements
Quantitative determination of copeptin (CT-proAVP)
values from serum samples was performed using an
immunoluminometric assay (Brahms CT-proAVP LIA,
Brahms GmbH, Hennigsdorf, Germany) on the tube
luminometer Lumat LB 9507 (Berthold Technologies
GmbH, Bad Wildbad, Germany). The functional sensi-
tivity of the assay was shown to be <1.0 pmol/l, an inter-
assay CV <10% was found for copeptin concentrations
>2.5 pmol/l. NT-proBNP serum values were quantified
using an electrochemiluminiscence (ECLIA) assay on the
Modular E170 analyser (Roche Diagnostics, Mannheim,
Germany). Serum creatinine was determined enzymati-
cally on the Modular P800 (Roche Diagnostics), and so-
dium values were quantified on the ISE900 by indirect
potentiometry (Roche Diagnostics).
Statistical analysis
Variables are presented as absolute numbers, percentage or
median (interquartile range). Differences in demographic,
clinical, biochemical and hemodynamic variables between
Table 1 Risk of death in relation to demographic, clinical,
hemodynamic and biochemical baseline assessment
A: Single parameter cox regression analysis for clinical,




Age (per 5 years↑) 1.0 (0.9 – 1.1) 0.464
Gender 1.3 (0.6 – 2.5) 0.521
6MWD (30 m↓) 1.3 (1.1- 15) 0.001
NYHA 2.4 (1.2 –3.4) 0.012
Edema 1.0 (0.5 – 1.2) 0.835
S-Na (1 mmol/l ↓) 1.1 (1.1 – 1.2) 0.023
Creatinine (per 10 μg/l ↑) 1.0 (1.0 – 1.2) 0.015
eGFR (CKD-EPI) (per 10 ml/min ↓) 1.4 (1.2 – 2.2) 0.013
NT-proBNP (per 100 pg/ml ↑) 1.2 (1.1 -1.5) 0.019
Copeptin (per 5 pmol/l ↑) 1.9 (1.4 – 2.4) 0.001
RA (per 1 mmHg ↑) 1.2 (1.0 – 1.4) 0.040
mPAP (per 5 mmHg ↑) 1.0 (0.8 – 1.4) 0.081
CI (0.5 ml/min/m2 ↓) 1.3 (1.2 – 1.6) 0.018
PVR (50 dyn · sec · cm-5 ↑) 1.1 (0.9 – 1.2) 0.105
SvO2 (−5% ↓) 1.3 (1.1 – 1.3) 0.017







S-Na (1 mmol/l ↓) 1.0 (0.9 – 1.2) 0.796
Creatinine (per 10 μg/l ↑) 0.7 (0.5 – 1.1) 0.819
eGFR (CKD-EPI) (per 10 ml/min ↓) 0.9 (0.9 – 1.0) 0.129
NT-proBNP (per 100 pg/ml ↑) 0.9 (0.8 – 1.2) 0.581
Copeptin (per 5 pmol/l ↑) 1.4 (1.1 -2.0) 0.015
Data are from the retrospective cohort (cohort 1).
Estimated HRs, 95% CIs, and p values were calculated by simple and forward
Cox regression analyses.
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York
Heart Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI)
estimated glomerular filtration calculated according the Chronic Kidney
Disease Epidemiology Collaboration formula, NT-proBNP N-terminal prohormone
of brain natriuretic peptide, RA right atrial pressure, mPAP mean pulmonary artery
pressure, CI cardiac index, PVR pulmonary vascular resistance, SvO2 mixed venous
oxygen saturation.
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Spearman rank correlation for continuous variables, χ2 test
for nominal variables, and NYHA class. Differences in
copeptin levels among the healthy and diseased controls
and the first PAH cohort and PAH-subgroups were
assessed using Kruskal–Wallis one-way analysis of variance.
Differences among patients with copeptin levels below or
above 13.2 pmol/l were calculated by using Mann–Whitney
U-test for continuous, and χ2-test for categorical variables.
Relations between copeptin level and baseline variables
were assessed by Spearman rank correlation coefficients.
The Wilcoxon signed rank test was used to compare
changes in variables after initiation of treatment.
For survival analysis death or lung transplantation was
defined a priori as the primary composite endpoint. For
Cox regression analysis variables were categorized as in-
dicated in Table 1. Simple Cox regression analyses were
performed to identify predictors of death. For multiple
stepwise forward Cox regression, copeptin was tested
with biochemical variables (N-terminal prohormone of
brain natriuretic peptide, creatinine, estimated glomeru-
lar filtration rate calculated according the Chronic
Kidney Disease Epidemiology Collaboration formula
(eGFR-CKD-EPI), serum sodium concentration). For
this analysis, variables with a p-value of less then 0.05
were entered and variables with a p-value of greater
than 0.1 were removed.
Receiver operating characteristics curves (ROC) of NT-
proBNP and copeptin were generated and c-statistics were
calculated to obtain the NT-proBNP and copeptin cutoff
with the highest sensitivity and specificity to predict the
risk of death or transplantation after 3 years in cohort 1.
Kaplan Meier curves were generated to estimate and
illustrate survival in patients.
Statistical significance between groups were assessed
using the Log-Rank (Mantel Cox) method.
P-values < 0.05 were considered statistically significant.
Results
Patient’s characteristics
The first (retrospective) patient cohort consisted of 92
patients (66% female) with a median age of 57 (IQR
48–69) years. Median follow up was 55 (IQR 39–72)
months. Of the 92 patients, 27 died (29%) and 3 under-
went lung transplantation (3%).
The second (prospective) cohort consisted of 15 patients
(62% female) with a median age of 58 (IQR 49–65) years.
No patient was lost to follow up.
The diseased control group consisted of 39 patients
(68% female) with a median age of 53 (IQR 37–71) years.
There were no significant differences in age or gender
between the PAH cohorts and the diseased control
group (Table 2). The final diagnoses of the diseased con-
trols were: chronic obstructive pulmonary disease (30%),sleep apnea (5%), valvular heart disease (8%), interstitial
lung disease (23%), connective tissue disease (34%). In pa-
tients with CTD the diagnoses related to dyspnea were
non-specific interstitial pneumonia, pleural effusion, atelec-
tasis, respiratory muscle weakness and pericardial effusion.
Baseline copeptin levels are elevated in patients with
PAH
The mean copeptin level of PAH patients was four to
five times higher compared to diseased controls and
ten times higher compared to healthy controls. Median









Age (years) 57 (48–69) 58 (49–65) 53 (37–71) 39 (27–53)
Gender (female%) 66 62 68 29
6MWD [m] 335 (248–427) 352 (295–413) 389 (280–510)
NYHA class [%]
I 0 0 40
II 24 20 42
III 71 67 18
IV 5 13 0
Edema [%] 39 45 14
S-Na [mmol/l] 139 (137–142) 140 (138–141) 142 (139–144)
Creatinine [μg/l] 83 (67–95) 85 (73–98) 79 (67–93)
eGFR (CKD-EPI) [ml/min] 83 (68–98) 103 (79–99) 89.4 (72–118)
NT-proBNP [pg/ml] 2125 (588–3225) 2063 (990–2466) 474 (80–698)
Copeptin [pmol/l] 20.1 (7–25) 24.5 (8–37) 5.1 (2–7) 1.8 (1.4 -2.2)
RA [mmHg] 6.1 (4–9) 7.7 (5–8) 1.9 (2.5)
PCWP [mmHg] 8.6 (5–11) 7.9 (4–9) 7.8 (3.0)
mPAP [mmHg] 46 (37–54) 49 (43–56) 17.6 (12–23)
CI [ml/min/m2] 2.4 (1.8-2.8) 1.9 (1.6-2.5) 2.6 (2.3-2.8)
PVR [dyn · sec · cm-5] 792 (469–1024) 1004 (696–1325) 191 (120–271)
SvO2 [%] 63.1 (57–70) 61.2 (56–68) 72 (67–77)
Diagnosis [%]
IPAH 64 63 -
PAH associated with Congenital heart disease 11 7 -
PAH associated with Connective tissue disease 25 30 -
Shown are baseline data from PAH cohort 1, cohort 2 as well as diseased and healthy controls.
Except for sex, NYHA class, edema and diagnosis (%), data are shown as median (interquartile range, IQR).
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York Heart Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI) estimated
glomerular filtration calculated according the Chronic Kidney Disease Epidemiology Collaboration formula, NT-proBNP N-terminal prohormone of brain natriuretic
peptide, RA right atrial pressure, PCWP pulmonary capillary wedge pressure, mPAP mean pulmonary artery pressure, CI cardiac index, PVR pulmonary vascular
resistance, SvO2 mixed venous oxygen saturation, IPAH idiopathic pulmonary arterial hypertension.
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(IQR 7–25) and 24.5 pmol/l (IQR 8–37) respectively.
There were no statistical significant differences between
patients with IPAH or APAH (Additional file 1: Table S4).
The median copeptin level in the diseased control group
was 5.1 pmol/l (IQR 2–7) and 1.8 pmol/l (IQR 1.4-2.2) in
the healthy controls. Both statistically different from the
two PAH cohorts (p < 0.001) (Table 2, Figure 1).
NT-proBNP and copeptin ROC analysis
Receiver operating characteristic of NT-proBNP and
copeptin to predict mortality after 3 years showed that
the area under the curve (AUC) for NT-proBNP was 0.71
(CI 0.59-0.83, 0.02) and 0.77 (CI 0.64 -0.86, p = 0.001) for
copeptin. The best cutoff level to predict survival for NT-
proBNP was 1288 pg/ml (sensitivity of 71%, specificity
of 63%) and 13.2pmol/l (sensitivity of 70%, specificityof 78%) for copeptin respectively (Additional file 2:
Figure S1).
Baseline copeptin levels correlate with parameters of
disease severity in PAH
Patients presenting with baseline copeptin levels above the
copeptin cutoff of 13.2 pmol/l presented with higher NYHA
class (p = 0.01), increased creatinine levels (p = 0.04), de-
creased eGFR-CKD-EPI (p = 0.03) and higher NT-proBNP
levels (p < 0.001). There were no significant differences in
both groups regarding demographic data, 6MWD, S-Na
concentration, presence of edema, or hemodynamic pa-
rameters (Table 3).
There was a significant correlation between NYHA
class and copeptin levels (r = 0.46, p < 0.01) (Table 4). Pa-
tients presenting in NYHA class II had lower levels of
copeptin compared to patients presenting in NYHA III
Figure 1 Copeptin levels in controls and patients with PAH
from cohort 1 at baseline. Data are shown as median (IQR).
Differences between the groups were assessed using Kruskal–Wallis
one-way analysis of variance. * indicates p < 0.05.
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l (IQR 14–28), vs. 35.9 pmol/l, (IQR 26–49) (p < 0.001)
(Additional file 3: Figure S2).
Copeptin levels were negatively correlated with 6MWD
(r = −0.26, p = 0.04) and eGFR-CKD-EPI (r = −0.32, p =
0.01). Circulating copeptin levels at baseline were not as-
sociated with serum sodium concentration frequency of
edema (r = 0.05, p = 0.39; r = 0.09, p = 0.45) but strongly
related to NT-proBNP levels (r = 0.59, p < 0.001). NT-
proBNP levels were related to 6MWD (r = −0.51, p < 0.01),Table 3 Baseline characteristics in relation to copeptin levels
Copeptin <13.2 pmol/l (n = 54)
Age (years) 55.2 (45–67)
Gender (%female) 72






S-Na [mmol/l] 139 (138–143)
Creatinine [μg/l] 87.2 (61–94)
eGFR (CKD-EPI) [ml/min] 87 (74–99)
NT-proBNP [pg/ml] 1562 (351–18)
RA [mmHg] 5.3 (2–8)
PCWP [mmHg] 8.8 (6–12)
mPAP [mmHg] 45 (32–67)
CI [ml/min/m2] 2.5 (1.9-2.9)
PVR [dyn · sec · cm-5] 777 (419–1032)
SvO2 [%] 65 (58–73)
PAH patients from cohort 1 were dichotomized according their copeptin levels (<13
hemodynamic variables from both groups were compared. Differences were calcula
categorical variables.
Except for sex, NYHA class and edema (%), data are shown as median (interquartile
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York Hear
glomerular filtration calculated according the Chronic Kidney Disease Epidemiology
peptide, RA right atrial pressure, PCWP pulmonary capillary wedge pressure, mPAP m
resistance, SvO2 mixed venous oxygen saturation.NYHA class (r = 0.29, p = 0.04), creatinine (r = 0.32, p =
0.01), eGFR-CKD-EPI (r = −0.40, p < 0.03), right atrial pres-
sure (RA) (r = 0.41, p < 0.01), cardiac index (CI) (r = −0.51,
p < 0.01), pulmonary vascular resistance (PVR) (r = 0.35,
p = 0.01) and mixed venous oxygen saturation (Sv02)
(r = −0.60, p < 0.01) (Table 4).
Baseline copeptin levels are associated with outcome
Univariate Cox Regression analysis showed that baseline
copeptin levels were a significant prognostic indicator of
poor outcome (HR 1.9, CI 1.4-2.4, p < 0.001). Multiple
forward Cox Regression analysis showed that copeptin
levels remained a significant predictor of mortality when
tested against NT-proBNP, serum sodium concentration
(S-Na) and eGFR CKD-EPI (HR 1.4; 95%, CI 1.1-2.0, p =
0.04) (Table 1).
Kaplan Meier survival analysis showed that patients
with a ROC derived cutoff copeptin level <13.2 pmol/
l at baseline had a significantly better survival compared
to patients with a copeptin level > 13.2 pmol/l (Figure 2).
The estimated median survival of patients with a copeptin
level <13.2 pmol/l was 103 months (IQR 132–84), com-
pared to 52 (IQR 84 – 24) months in patients with a



















.2 pmol/l or >13.2 pmol/l) and demographic, clinical, biochemical and
ted by using Mann–Whitney U-test for continuous and χ2 -test for
range, IQR).
t Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI) estimated
Collaboration formula, NT-proBNP N-terminal prohormone of brain natriuretic
ean pulmonary artery pressure, CI cardiac index, PVR pulmonary vascular
Table 4 Correlations of serum copeptin levels and serum
NT-proBNP levels with demographic, clinical, biochemical
and hemodynamic parameters
Copeptin NT-proBNP
Parameter rho p rho p
Age (years) 0.21 0.05 0.18 0.21
Gender (female%) 0.13 0.09 −0.85 0.49
6MWD [m] −0.26 0.04 −0.51 0.01
NYHA class 0.46 0.01 0.29 0.04
Edema 0.06 0.48 0.168 0.18
S-Na [mmol/l] 0.19 0.45 −0.03 0.83
Creatinine [μg/l] 0.39 0.01 0.32 0.01
eGFR (CKD-EPI) [ml/min] −0.32 0.01 −0.40 0.03
NT-proBNP [pg/ml] 0.49 0.01 - -
Copeptin [pmol/l] - - 0.49 0.01
RA [mmHg] 0.19 0.06 0.41 0.01
PCWP 0.09 0.41 0.23 0.14
mPAP [mmHg] 0.06 0.91 0.23 0.07
CI [ml/min/m2] −0.14 0.18 −0.51 0.01
PVR [dyn · sec · cm-5] 0.06 0.57 0.35 0.01
SvO2 [%] −0.22 0.07 −0.60 0.01
Data are from the retrospective cohort (cohort 1).
The relations between copeptin and NT-proBNP levels and baseline variables
were assessed by Spearman rank correlation coefficients.
Significant correlations are highlighted in boldface.
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York
Heart Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI)
estimated glomerular filtration calculated according the Chronic Kidney
Disease Epidemiology Collaboration formula, NT-proBNP N-terminal prohormone
of brain natriuretic peptide, RA right atrial pressure, PCWP pulmonary capillary
wedge pressure, mPAP mean pulmonary artery pressure, CI cardiac index,
PVR pulmonary vascular resistance, SvO2 mixed venous oxygen saturation.
Copeptin <13.2pmol/l 54 54 43 32
Copeptin >13.2pmol/l 38 34 24 15

















Number of remaining ca
Figure 2 Probability of survival according to baseline copeptin levels
Nickel et al. Respiratory Research 2013, 14:130 Page 6 of 9
http://respiratory-research.com/content/14/1/130Baseline copeptin levels add prognostic information to
baseline NT-proBNP levels
Kaplan Meier survival analysis showed that patients with
a ROC derived cutoff NT-proBNP level <1288 pg/ml
and a copeptin level <13.2 pmol/l at baseline had signifi-
cant better chances of survival compared to patients
with an elevation above the cutoff in both biomarkers.
The estimated median survival of patients with a NT-
proBNP and copeptin below the ROC derived cutoffs
was 114 month (IQR 128–89), compared to 47 month
(IQR 61–33) in patients with an elevation in both bio-
markers (p < 0.001) (Figure 3).
Copeptin levels decrease after initiation of PAH targeted
treatment
After initiation of PAH targeted therapy, there was significant
improvement in all measured pulmonary hemodynamic var-
iables. Changes in NYHA class and 6MWD did not reach
clinical significance. Copeptin levels decreased signifi-
cantly from 24.5 pmol/l at baseline to 15.8 pmol/l after 3
to 6 months of treatment (p = 0.01) (Additional file 1:
Table S1).
Changes in copeptin levels did not correlate with
changes in pulmonary or systemic hemodynamic param-
eters. There was no correlation between changes in
6MWD, eGFR-CKD-EPI, S-Na and changes in copeptin,
however the association between changes in NT-
proBNP and changes in copeptin was significant (r =
0.53, p = 0.01) (Additional file 1: Table S3).
Discussion
Copeptin as a New biomarker in PAH
Copeptin has emerged as a promising surrogate target
for measurement of vasopressin concentration and also
seems useful in cardiovascular disease [21,22].27 22
10 7
48 60
Copeptin < 13.2 pmol/l
Copeptin > 13.2 pmol/l
ses
above or below the ROC derived cutoff of 13.2 pmol/l.
NT-proBNP low
Copeptin low
40 38 31 19 18 15
NT-proBNP low
Copeptin high
10 10 9 7 5 4
NT-proBNP high
Copeptin low
17 17 14 11 8 7
NT-proBNP high
Copeptin high
25 23 13 10 6 3
















NT-proBNP low/ Copeptin low
NT-proBNP low/ Copeptin high
NT-proBNP high/ Copeptin low
NT-proBNP high/ Copeptin high
p=0.001
Number of remaining cases
Figure 3 Probability of survival according to baseline NT-proBNP and copeptin levels above or below the ROC derived cutoffs.
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copeptin levels compared to patients without a diagnosis of
PAH. Increased copeptin levels were associated with a higher
risk of death and an independent predictor of poor outcome.
Copeptin levels were significantly correlated with
NYHA class, 6MWD and kidney function, all of which
being indicators of more severe disease and poor out-
come in PAH patients [3,23-25].
As reported in patients with left ventricular heart fail-
ure [14] PAH patients showed a strong association be-
tween copeptin and NT-proBNP levels at baseline and
after initiation of treatment. It is known (and confirmed
in this study) that NT-proBNP shows clear associations
with pulmonary hemodynamics and it is released mainly
by the right atrium in PAH patients [16,26]. Given the in-
dependence of copeptin from pulmonary hemodynamics
and the consistent correlation with NT-proBNP at base-
line and after beginning of PAH targeted therapy, copeptin
levels might reflect neurohumoral activation due to al-
tered right ventricular function. Therefore elevated copep-
tin levels at baseline and during follow up could add
important prognostic information that is not captured by
right heart catheterization or NT-proBNP levels alone.
Multimarker strategies for risk stratification are increas-
ingly used in patients with coronary syndrome [27] and
left heart failure [15,28].
Copeptin was shown to provide additional information
to troponin in the triage of chest pain patients and to
improve the diagnostic performance of NT-proBNP in
predicting risk of all-cause mortality in patients with
chronic heart failure [22,28].Given the limitations of a NT-proBNP when it comes
to predicting individual outcomes in PAH, the combin-
ation of copeptin with NT-proBNP might help to distin-
guish a patient population with particular high risk for
fatal outcome.
Copeptin and indicators of neurohumoral activation in
PAH
Peripheral edema and ascites are common presentations
in patients with advanced PAH and indicators of in-
creased neurohumoral activation. The role of neurohu-
moral mediators in PAH is of great interest since the
pathophysiology of volume overload in right heart failure
is not well understood. There is cumulating evidence
for increased neurohumoral activation in PAH. It was
shown that PAH patients have elevated levels of nor-
epinephrine [16], renin, aldosterone, elevated plasma
volume and hyponatremia in advanced disease [17-20]. In
this report we show that copeptin levels are also strikingly
elevated in PAH, providing further evidence for increased
neurohumoral activation in those patients.
Unlike previously reported in patients with chronic left
heart failure [14] we found no significant correlation be-
tween circulating copeptin levels and other indicators of
increased neurohumoral activation (e.g. decreased serum
sodium concentrations or the presence of edema). One
explanation could be a lack of statistical power in this
study due to relatively low sample size compared to
studies in patients with left heart failure. However, a re-
cent clinical study in acute heart failure patients did also
find no association of right ventricular preload, copeptin
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edema [29].
Decreased serum sodium concentration and peripheral
edema in chronic heart failure are associated with
chronically elevated levels of neurohumoral mediators,
and are usually seen in late disease stages when decom-
pensation occurs. Activation of the AVP system, mea-
sured by copeptin levels, in contrast, appears to occur
early in the course of the disease.
Taken together, these data might suggest that activation
of the AVP system - measured by copeptin levels - is
not the primary cause of volume overload and hypo-
natremia among patients with right heart strain, but
might reflect an early indication of neurohumoral stimu-
lation. But the exact relationship between neurohumoral
hormones and other mediators of sodium and fluid
homeostasis in the setting of right heart strain needs fur-
ther investigation.
Vasopressin in right ventricular failure
Vasopressin release is triggered following reduced car-
diac output and activation of baroreceptors in the ca-
rotid sinus [30] leading to systemic vasoconstriction and
renal water retention [5].
The lack of association of copeptin with cardiac output
and mixed venous oxygen saturation, but the strong cor-
relation with functional parameters like 6MWD and
NYHA class provides evidence that activation of the AVP-
system reflects an interplay of a variety of different factors,
rather than cardiac function alone, that determine overall
cardiovascular performance in PAH patients.
The decrease of copeptin levels after initiation of PAH
targeted therapy suggests that longitudinal copeptin mea-
surements might provide important information about
cardiovascular stress and response to treatment.
Excessive neurohumoral activation contributes to the
development of symptoms of heart failure by altering
vascular resistance, blood volume and cardiac contractil-
ity [31]. In addition, vasopressin is involved in cardiac
remodeling via its V1receptor on cardiomyocytes, lead-
ing to increased protein-synthesis, cardiac hypertrophy,
decreased contractility and development of myocardial
fibrosis [32,33]. These observations, although mostly
derived from the left ventricle, raise the possibility
that elevated vasopressin levels in PAH patients might
also play a role in right ventricular remodeling [34].
Limitations of the study
This was a single-center, mostly retrospective study with
a limited sample size, especially in the prospective co-
hort. Given the descriptive nature of the current study,
this manuscript does not address the causes or physio-
logic mechanisms for elevated copeptin levels in patients
with PAH.Conclusions
Circulating copeptin levels are elevated in patients with
PAH and have the potential to become useful bio-
markers in the assessment of PAH patients adding inde-
pendent information to the clinical, biochemical and
hemodynamic assessment.Additional files
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Copeptin levels in PAH-Subgroups from PAH cohort 1. Table S5.
Adjusted risk of death in relation to copeptin. Table S6. Risk of death in
relation to significant variables from the single parameter cox regression
analysis.
Additional file 2: Figure S1. Receiver Operating Characteristic Curve
Analyses and Area Under The Curve Statistics Relating NT-proBNP and
Copeptin Levels To 3-year Outcome In Cohort 1.
Additional file 3: Figure S2. Copeptin Levels According To NYHA Class
From Cohort 1. Data are shown as median (IQR). Differences between the
groups were assessed using Kruskal-Wallis one-way analysis of variance.
*indicates p < 0.05.Abbreviations
6MWD: Six minute walking distance; CI: Cardiac index; eGFR: Estimated
glomerular filtration rate; eGFR-CKD-EPI: Estimated glomerular filtration
calculated according the chronic Kidney disease epidemiology collaboration
formula; mPAP: Mean Pulmonary Arterial pressure; NT-proBNP: N-terminal
prohormone of brain natriuretic peptide; NYHA: New York Heart Association;
PAH: Pulmonary arterial hypertension; PCWP: Pulmonary capillary wedge
pressure; PVR: Pulmonary vascular resistance; RA: Right atrial pressure;
S-Na: Serum Sodium Concentration; SvO2: Mixed venous oxygen saturation.
Competing interest
None of the authors has any conflict of interest with the data published in
this manuscript. NPN: received funding from Deutsche
Forschungsgemeinschaft (DFG). RL: has nothing to disclose. HG: is member
of the advisory board of Roche pharmaceuticals and Boehringer
Pharmaceuticals, and received lecture fees from Pfizer pharmaceuticals. KMO:
received lecturing and traveling fees from Pfizer and Actelion. KB: has
nothing to disclose. TW: is member of the advisory board of Brahms
pharmaceuticals and received lecturing fees from Brahms and Bio Merieux
pharmaceuticals. MMH: received consultant and lecture fees from Actelion,
Bayer, GSK, Lilly, Pfizer, Novartis.
Authors’ contribution
NPN contributed to study design, acquisition, analysis and interpretation of
the data and wrote the manuscript. RL contributed to copeptin, NT-pro-BNP
measurements. He contributed to study design and interpretation of the
data. HG contributed to data and sample acquisition and edited the manuscript.
KMO contributed to data and sample acquisition and edited the manuscript. KB
contributed to copeptin, NT-pro-BNP measurements. TW supervised the project.
MMH designed the study, interpreted the data and wrote the paper. NPN had
full access to all the data in the study and that he takes responsibility for the
integrity of the data and the accuracy of the data analysis. All authors read and
approved the final manuscript.
Author details
1Department of Respiratory Medicine, Hannover Medical School, 30623
Hannover, Germany. 2German Center of Lung Research, Hannover, Germany.
3Institute for Clinical Chemistry Hannover Medical School, Hannover,
Germany.
Nickel et al. Respiratory Research 2013, 14:130 Page 9 of 9
http://respiratory-research.com/content/14/1/130Received: 24 June 2013 Accepted: 16 October 2013
Published: 19 November 2013References
1. Archer SL, Weir EK, Wilkins MR: Basic science of pulmonary arterial
hypertension for clinicians: new concepts and experimental therapies.
Circulation 2010, 121:2045–2066.
2. Swiston JR, Johnson SR, Granton JT: Factors that prognosticate mortality
in idiopathic pulmonary arterial hypertension: a systematic review of the
literature. Respir Med 2010, 104:1588–1607.
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA,
Beghetti M, Corris P, Gaine S, Gibbs JS, et al: Guidelines for the diagnosis
and treatment of pulmonary hypertension: the task force for the
diagnosis and treatment of pulmonary hypertension of the European
society of cardiology (ESC) and the European respiratory society (ERS),
endorsed by the international society of heart and lung transplantation
(ISHLT). Eur Heart J 2009, 30:2493–2537.
4. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure.
N Engl J Med 1999, 341:577–585.
5. Antunes-Rodrigues J, de Castro M, Elias LL, Valenca MM, McCann SM:
Neuroendocrine control of body fluid metabolism. Physiol Rev 2004,
84:169–208.
6. Treschan TA, Peters J: The vasopressin system: physiology and clinical
strategies. Anesthesiology 2006, 105:599–612. quiz 639–540.
7. Holmes CL, Landry DW, Granton JT: Science review: vasopressin and the
cardiovascular system part 1–receptor physiology. Crit Care 2003,
7:427–434.
8. Robertson GL, Mahr EA, Athar S, Sinha T: Development and clinical
application of a new method for the radioimmunoassay of arginine
vasopressin in human plasma. J Clin Invest 1973, 52:2340–2352.
9. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the
measurement of copeptin, a stable peptide derived from the precursor
of vasopressin. Clin Chem 2006, 52:112–119.
10. Land H, Schutz G, Schmale H, Richter D: Nucleotide sequence of cloned
cDNA encoding bovine arginine vasopressin-neurophysin II precursor.
Nature 1982, 295:299–303.
11. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Muller B,
Christ-Crain M: Anterior and posterior pituitary function testing with
simultaneous insulin tolerance test and a novel copeptin assay. J Clin
Endocrinol Metab 2007, 92:2640–2643.
12. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical
use of a new biomarker. Trends Endocrinol Metab 2008, 19:43–49.
13. Morgenthaler NG: Copeptin: a biomarker of cardiovascular and renal
function. Congest Heart Fail 2010, 16(Suppl 1):S37–S44.
14. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG,
Bergmann A, Moertl D, Berger R, Pacher R: Comparison of copeptin, B-type
natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in
patients with chronic heart failure: prediction of death at different stages
of the disease. J Am Coll Cardiol 2008, 52:266–272.
15. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann
A, Platonov PG, Hedblad B, Engstrom G, Wang TJ, Melander O: Assessment
of conventional cardiovascular risk factors and multiple biomarkers for
the prediction of incident heart failure and atrial fibrillation. J Am Coll
Cardiol 2010, 56:1712–1719.
16. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S:
Neurohormonal activation in patients with right ventricular failure from
pulmonary hypertension: relation to hemodynamic variables and
endothelin levels. J Am Coll Cardiol 1995, 26:1581–1585.
17. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I,
Dorfmuller P, Simonneau G, Fadel E, et al: Dysregulated renin-angiotensin-
aldosterone system contributes to pulmonary arterial hypertension. Am J
Respir Crit Care Med 2012, 186:780–789.
18. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P:
Increased sympathetic nerve activity in pulmonary artery hypertension.
Circulation 2004, 110:1308–1312.
19. James KB, Stelmach K, Armstrong R, Young JB, Fouad-Tarazi F: Plasma
volume and outcome in pulmonary hypertension. Tex Heart Inst J 2003,
30:305–307.
20. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion
HC, Girgis RE, Hassoun PM: Hyponatremia predicts right heart failure andpoor survival in pulmonary arterial hypertension. Am J Respir Crit Care
Med 2008, 177:1364–1369.
21. Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M,
Ishikawa SE: Possible vascular role of increased plasma arginine
vasopressin in congestive heart failure. Int J Cardiol 2006, 106:191–195.
22. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C,
Baldus S, Sinning CR, et al: Copeptin improves early diagnosis of acute
myocardial infarction. J Am Coll Cardiol 2010, 55:2096–2106.
23. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS,
Frost A, Barst RJ, Badesch DB, Elliott CG, et al: Predicting survival in
pulmonary arterial hypertension: insights from the registry to evaluate
early and long-term pulmonary arterial hypertension disease
management (REVEAL). Circulation 2010, 122:164–172.
24. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM,
Fishman AP, Goldring RM, Groves BM, Kernis JT, et al: Survival in patients
with primary pulmonary hypertension. Results from a national
prospective registry. Ann Intern Med 1991, 115:343–349.
25. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M:
Association of serum creatinine with abnormal hemodynamics and
mortality in pulmonary arterial hypertension. Circulation 2008,
117:2475–2483.
26. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr: Atrial natriuretic peptide
in heart failure. J Am Coll Cardiol 1993, 22:86A–92A.
27. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr,
Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, et al: ACC/AHA 2007
guidelines for the management of patients with unstable angina/non
ST-elevation myocardial infarction: a report of the American college of
cardiology/American heart association task force on practice guidelines
(writing committee to revise the 2002 Guidelines for the management
of patients with unstable angina/Non ST-elevation myocardial infarction):
developed in collaboration with the American college of emergency
physicians, the society for cardiovascular angiography and interventions,
and the society of thoracic surgeons: endorsed by the American association
of cardiovascular and pulmonary rehabilitation and the society for academic
emergency medicine. Circulation 2007, 2007(116):e148–e304.
28. Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP: Association of copeptin and
N-terminal proBNP concentrations with risk of cardiovascular death in older
patients with symptoms of heart failure. JAMA 2011, 305:2088–2095.
29. Breidthardt T, Irfan A, Klima T, Drexler B, Balmelli C, Arenja N, Socrates T,
Ringger R, Heinisch C, Ziller R, et al: Pathophysiology of lower extremity
edema in acute heart failure revisited. Am J Med 2012, 125:1124. e1121-1128.
30. Ebert TJ, Cowley AW Jr, Skelton M: Vasopressin reduces cardiac function
and augments cardiopulmonary baroreflex resistance increases in man.
J Clin Invest 1986, 77:1136–1142.
31. Benedict CR JC, Weiner DH, Bourassa MG, Bittner V, Kay RKP, Greenberg B,
Kohn RM, Nicklas JM, Mclntyre K, Quinones MAYS: Relation of
neurohormoral activation to clinical variables and degree of ventricular
dysfunction: a report from the registry of studies of left ventricular
dysfunction. J Am Coil Cardiol 1994, 23:1410–1420.
32. Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC, Yang XD: Arginine
vasopressin increases iNOS-NO system activity in cardiac fibroblasts
through NF-kappaB activation and its relation with myocardial fibrosis.
Life Sci 2007, 81:327–335.
33. Fukuzawa J, Haneda T, Kikuchi K: Arginine vasopressin increases the rate
of protein synthesis in isolated perfused adult rat heart via the V1
receptor. Mol Cell Biochem 1999, 195:93–98.
34. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF: The right ventricle
under pressure: cellular and molecular mechanisms of right-heart failure
in pulmonary hypertension. Chest 2009, 135:794–804.
doi:10.1186/1465-9921-14-130
Cite this article as: Nickel et al.: Circulating levels of copeptin predict
outcome in patients with pulmonary arterial hypertension. Respiratory
Research 2013 14:130.
